Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment



Rating:

Share or cite this content

Citations should be made in the following way:
R. Frey, C. Becker, S. Unger, A. Schmidt, G. Wensing, W. Mueck (Wupperal, Wuppertal, Germany). Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment. Eur Respir J 2013; 42: Suppl. 57, 4073

Member's Comments

No comment yet.

Related content which might interest you: First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Source: Eur Respir J 2009; 33: 785-792 Year: 2009 Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009 Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Source: Eur Respir Rev 2009; 19: 68-71 Year: 2010 Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 A soluble guanylate cyclase stimulator, BAY 41-8543, preserves pulmonary artery endothelial function in experimental pulmonary embolism Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial Source: Eur Respir J 2013; 41: 853-860 Year: 2013 The stimulator of soluble guanylate cyclase riociguat protects against bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 Effects of a soluble guanylate cyclase stimulator, BAY 41-8543, upon right ventricular function in experimental pulmonary embolism Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008 Soluble guanylate cyclase stimulator riociguat prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Source: Annual Congress 2011 - Translational models of disease Year: 2011 Effect of omeprazole and AlOH/MgOH on riociguat absorption Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Activation of AMPK inhibits pulmonary arterial remodeling Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001